A serotonin receptor antagonists for therapeutic treatment
Inventors
Borsini, Franco • Evans, Kenneth Robert
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-7151103-B2
Publication Date
2006-12-19
Expiration Date
Abstract
The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
Core Innovation
The disclosed invention relates to flibanserin and pharmaceutically acceptable acid addition salts for preparing medicaments for treating female hypoactive sexual desire disorder. The document indicates use in patients in need thereof to treat inhibited sexual desire, loss of libido, libido disturbance, and related conditions such as frigidity.
The medicaments include flibanserin receptor affinity, with receptor affinity to 5-HT1A receptor and 5-HT2 receptor. The document further provides flibanserin in the form of pharmaceutically acceptable acid addition salts, with acid salt options including hydrochloride, hydrobromide, succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesulphonic acid, lactic acid, phosphoric acid, sulphuric acid, tartaric acid, citric acid, and mixtures.
The disclosure also describes pharmaceutical formulations for administering flibanserin or the pharmaceutically acceptable acid addition salt as medicaments, including oral administration, rectal administration, parenteral administration, and nasal inhalation. Example pharmaceutical formulations are described as tablets, coated tablets, capsules, ampoule solution, and suppositories using flibanserin hydrochloride.
Claims Coverage
The patent document contains 1 independent claim directed to treating female hypoactive sexual desire disorder by administering flibanserin or a pharmaceutically acceptable acid addition salt in a therapeutically effective amount. The dependent claims further specify the acid(s) used for the salt form and a daily dose range.
Treating female hypoactive sexual desire disorder with flibanserin or acid addition salt
A method of treating a female hypoactive sexual desire disorder in a patient comprising administering to said female patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said female hypoactive sexual desire disorder.
Acid addition salt using enumerated acids
The method includes administering flibanserin as a pharmaceutically acceptable acid addition salt formed by adding an acid selected from succinic acid, hydrobromic acid, acetic acid, fumaric acid, maleic acid, methanesuiphonic acid, lactic acid, phosphonic acid, hydrochloric acid, sulphuric acid, tartaric acid, citric acid and mixtures thereof.
Daily dose range for treating female hypoactive sexual desire disorder
The method is carried out by administering flibanserin or a pharmaceutically acceptable acid addition salt at a daily dose ranging from 0.1 to 400 mg per day.
Overall, the claims cover treating female hypoactive sexual desire disorder by administering flibanserin or a pharmaceutically acceptable acid addition salt in a therapeutically effective amount, with further limitations specifying enumerated acids for the salt form and a daily dose range of 0.1 to 400 mg per day.
Stated Advantages
Treats female hypoactive sexual desire disorder.
Treats loss of sexual desire and decreased sexual desire (loss of libido, libido disturbance).
Documented Applications
Preparing medicaments for treating female hypoactive sexual desire disorder, including loss of sexual desire and decreased sexual desire (loss of libido, libido disturbance).
Treating female hypoactive sexual desire disorder by administering flibanserin or a pharmaceutically acceptable acid addition salt.
Interested in licensing this patent?